Injury guide

UPDATED FEB 2026

Hair Relaxer Uterine Cancer

Part of the Hair Relaxer Cancer investigation

The short answer

Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users.

Approximately 67,000 Americans are diagnosed with uterine cancer annually.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

How Hair Relaxers Cause Uterine Cancer

Chemical hair relaxers contain endocrine-disrupting chemicals that mimic estrogen when absorbed through the scalp. Chronic estrogen overstimulation drives abnormal cell growth in the uterine endometrium — the mechanism underlying most endometrial cancers. The Sister Study's hazard ratio of 2.55 means frequent relaxer users face more than double the uterine cancer risk of non-users.

Uterine Cancer Survival and Treatment

When caught early (Stage I), uterine cancer has a 5-year survival rate of about 95%. But advanced-stage disease has much worse outcomes. Treatment typically involves hysterectomy (removal of the uterus), often with bilateral salpingo-oophorectomy (removal of ovaries), radiation, and possibly chemotherapy. For younger women, this means permanent loss of fertility.

The Racial Disparity

Black women die of uterine cancer at twice the rate of white women — one of the largest racial disparities in cancer mortality. This disparity has been attributed to later diagnosis, more aggressive tumor subtypes, and barriers to care. The hair relaxer litigation adds another factor: disproportionate exposure to EDC-containing products specifically marketed to Black women.

Building Your Uterine Cancer Claim

Key evidence: medical records documenting uterine cancer diagnosis and treatment, history of regular hair relaxer use (product names, frequency, duration), pathology reports (tumor type and stage), and timeline showing cancer diagnosis followed prolonged relaxer use.

Research & evidence

Scientific Evidence

Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study

Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research

View on PubMed

Use of Straighteners and Other Hair Products and Incident Uterine Cancer

Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute

View on PubMed

Use of Hair Products in Relation to Ovarian Cancer Risk

White AJ, Sandler DP, et al. (2021). Carcinogenesis

View on PubMed

FAQ

Frequently Asked Questions

36 QUESTIONS

Chemical hair relaxers contain endocrine-disrupting chemicals (EDCs) — phthalates, parabens, formaldehyde, BPA, and cyclosiloxanes — that mimic estrogen when absorbed through the scalp. Chronic estrogen overstimulation promotes abnormal growth in hormone-sensitive tissues. The NIH Sister Study found that frequent relaxer users face a 155% increased risk of uterine cancer and a 119% increased risk of ovarian cancer.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Hair Relaxer Cancer Investigation